Melasma
Conditions
Interventions
Experimental Group:Peptide AOP-P1 is soluble in 20% propylene glycol solvent
Control Group:Only 20% propylene glycol was used
Sponsors
First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Voluntarily participate in this experiment, give informed consent to the purpose and content of the study, and be willing to complete the research process. Sign the informed consent form and agree to use the product; (2) The subjects have reasonable expectations, are able to understand and comply with the instructions and all visit schedules; (3) Complies with the diagnosis of melasma; Not receiving any laser treatment, chemical exfoliation, or internal or external medication treatment within one month prior to treatment; Women aged between 18 and 40.
Exclusion criteria
Exclusion criteria: (1) Patients who have not filled out the informed consent form and are unwilling to participate in the experiment or have not signed the informed consent form; (2) For patients who are allergic to the known ingredients of the experimental drug, the ingredients are as follows: propylene glycol (3) Pregnant women, breastfeeding women, and women with family planning; (4) Patients with other skin injuries or other facial pigmentation disorders (such as brown blue nevi, vitiligo, Riehl's melanosis, brown black disease, etc.) that may affect the experimental results; (5) Received any laser treatment, chemical exfoliation, or internal or external medication treatment within one month prior to treatment; (6) Patients who are currently participating in other clinical trials and have participated in other clinical trials within 30 days or are in the exclusion period of a clinical trial; (7) Those who cannot strictly avoid light or sun protection (such as those who are allergic to sunscreen, long-term outdoor workers, or those who are exposed to high ultraviolet radiation in their daily living environment) or those who take photosensitive drugs orally; (8) Patients with other diseases such as psoriasis, atopic dermatitis, scar constitution, congenital or acquired immune deficiency, autoimmune diseases, skin cancer, photosensitivity (diabetes, thyroid disease, liver and kidney disease, photosensitive skin disease), cardiovascular disease, facial acute dermatitis and infectious diseases (such as herpes simplex); (9) Those who have incomplete clinical data that affects the assessment of efficacy or are unable to cooperate in completing the evaluation and mental disorders, or those who cannot follow the experimental protocol to terminate treatment or change treatment methods during the treatment period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective evaluation;MASI score;VISIA Image Analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| CK Mirror Analysis;LAB and dermatoscopy examination; | — |
Countries
China
Contacts
Public ContactDan Xu
The First Affiliated Hospital of Kunming Medical University
Outcome results
None listed